TP53 and neoplasm: The latter lacks the amino-terminal transactivation domain and hence acts as a dominant negative inhibitor of both TAp73 and p53, giving rise to the notion that TAp73 is a tumor suppressor like p53, whereas ΔNp73 is an oncogene (17).